Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC, Apatinib, and Camrelizumab in Unresectable MTM-HCC
NCT05839197Phase 2Recruiting
- Start
- May 2023
- Primary completion
- Apr 2025
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label trial of camrelizumab and Rivoceranib in hepatocellular carcinoma (HCC). Primary endpoint: Objective Remission Rate at 1 year. Started May 2023; status: recruiting.
02
Drugs
camrelizumabRivoceranib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05839197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05839197.